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Abstract Chronic paroxysmal hemicrania (CPH) is a rare
primary headache syndrome, which is classiﬁed along with
hemicrania continua and short-lasting unilateral neuralgi-
form headache attacks with conjunctival injection and
tearing (SUNCT) as trigeminal autonomic cephalalgia
(TACs). CPH is characterised by short-lasting (2–30 min),
severe and multiple (more than 5/day) pain attacks.
Headache is unilateral, and fronto-orbital-temporal pain is
combined with cranial autonomic symptoms. According to
the International Classiﬁcation of Headache Disorders, 2nd
edition, the attacks are absolutely responsive to indo-
methacin. CPH has been only rarely and incompletely
described in the developmental age. Here, we describe two
cases concerning a 7-year-old boy and a 11-year-old boy
with short-lasting, recurrent headache combined with cra-
nial autonomic features. Pain was described as excruciat-
ing, and was non-responsive to most traditional analgesic
drugs. The clinical features of our children’s headache and
the positive response to indomethacin led us to propose the
diagnosis of CPH. Therefore, our children can be included
amongst the very few cases of this trigeminal autonomic
cephalgia described in the paediatric age.
Keywords Chronic paroxysmal hemicrania  Trigeminal
autonomic cephalgias  Children  Indomethacin
Introduction
Headache is a notable and common somatic complaint in
paediatric age [1, 2]. Although migraine and tension-type
headache show the highest incidence, other primary
headaches are much rarer and poorly recognised, thus
representing a clinical and therapeutic challenge.
Chronic paroxysmal hemicrania (CPH) is a rare and
well-characterised headache, classiﬁed amongst the tri-
geminal autonomic cephalgias (TACs) [3]. CPH is char-
acterised by short-lasting (2–30 min) and multiple pain
attacks, with a typical attack frequency of more than 5 per
day [3–6].
Pain is unilateral, located on the fronto-orbital-temporal
region, it has rapid onset and it is described as excruciating.
Attacks occur in combination with al least one ipsilateral
autonomic symptom, such as conjunctival injection, lach-
rymation, miosis, ptosis, eyelid oedema, and nasal con-
gestion or rhinorrhea [3, 7].
The standard CPH treatment is based on the use of
indomethacin. The absolute pain responsiveness to indo-
methacin represents one of the diagnostic criteria for CPH
[3] (Table 1).
Because of its typical onset between 20 and 30 years of
age [5, 6], CPH has been extensively studied in adult
population. The disease can occur, although more rarely,
also in children [8–16], as early as from the age of 3
[9, 12]. However, few reports in paediatric age fulﬁlled the
diagnostic criteria for CPH [9, 10, 12] according to the
International Classiﬁcation of Headache Disorders, 2nd
edition (ICHD-II) [3] (Table 2). In particular, the presence
of autonomic signs and response to indomethacin has not
been discussed adequately [11, 14, 15, 18]. Some unilateral
short-lasting paediatric headaches without autonomic signs
have been diagnosed as CPH [15, 18]. Moorjani described
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responsive to indomethacin, but the attack duration and the
autonomic symptoms were not speciﬁed [18]. Despite the
complete response to indomethacin is one of the diagnostic
criteria [3], in some CPH children, the response to indo-
metachin was not tested [11, 14] or this was done only in
part [15]. Moreover, even one case of headache symp-
tomatic of a cerebral infarction has been reported as
CPH [16].
Here, we describe two children, referred to our Head-
ache Centre, with typical CPH features and a positive
response to indomethacin therapy.
Case 1
L., a 7-year-old boy, was referred to our Headache Center
because of a headache that had started 1-year earlier.
He suffered from unilateral pain, located in the right
orbito-frontal region without side shift; pain intensity was
excruciating, and its quality was described as throbbing.
Attack duration was variable, ranging from 5 to 30 min.
Headache occurred 1–3 times per day, during daytime and
night-time, without circadian rhythm. Pain was combined
with ipsilateral autonomic symptoms, such as conjunctival
injection, eyelid oedema and rhinorrhea. During the
attacks, the patient cried and found difﬁcult to lie still
showing marked agitation and restlessness. Moreover,
migraine-like features, such as vomiting and photophobia,
were also present. No trigger factors were detected. Psy-
chomotor development and neurological examinations did
not suggest any neurological damage. Skull CT scan, brain
MRI, also including the angiographic sequences, and EEG,
were normal. In addition, the blood tests and the blood
pressure were normal. The boy had a positive familiar
history of headache. In particular, his mother had migraine
attacks when she was young.
L. was submitted to psychological screening tests
(SAFA A, D, S scales) which showed normal anxiety,
depression and somatization indices [19].
During the headache attack, pain intensity was not
affected by most non-steroidal anti-inﬂammatory drugs
(NSAIDs), including acetaminophen, ketoprofen, and aspi-
rin. A prophylactic treatment with amitriptyline 16 mg/day
was attempted, with no improvement in attack frequency,
nor in pain intensity. When considering the headache char-
acteristics, the clinical history and the failure of most anal-
gesicdrugs,aprophylactictreatmentwithindomethacinwas
started, at the initial dose of 25 mg/day. The attack fre-
quency immediately showed a strong reduction, decreasing
from 1 to 3 attack/day to 2–3 attacks/month. Moreover,
the child’s parents were invited to use indomethacin 25 mg
for each single pain attack, and they reported a strong
pain relief. After 6 months, the parents discontinued the
treatment voluntarily, and the headache worsened consid-
erably. Over the following 9 months, ﬂunarizine 5 mg/day
was attempted, as suggested by another Headache Centre,
withoutanyamelioration.Conversely,asatisfactoryimprove-
ment was obtained after the resumption of indomethacin
25 mg/day (attack frequency of 3–4 per months). A further
reductioninheadacheattackfrequencyupto1–2 monthswas
obtainedwhentopiramatewasaddedatthedoseof45 mg/day
(corresponding to 1.5 mg/kg/day). However, due to an
attentive performance reduction, probably caused by topira-
mate, this drug was discontinued and replaced by sodium
valproate at the dose of 600 mg/day. The new treatment
obtainedpositiveeffects,withoutmajoradverseevents.When
L. was 9 years, the dose of indomethacin was increased up to
50 mg/day, with a mean attack frequency of 1 per month and
without any side effect, as also conﬁrmed by periodic blood
examinations.
Case 2
A., a 11-year-old Romanian boy, presented with a 3-year
history of recurrent daily headache. He described episodes
of severe throbbing pain attacks in the left fronto-orbital-
temporal region. Attacks were short-lasting (ranging from
5 to 40 min), and they occurred 3–4 times per day. Attacks
occurred during daytime and night-time, without nocturnal
predominance, nor circadian rhythm, and most of them
were combined with ipsilateral lachrymation, conjunctival
injection, ptosis and nasal congestion. Pain was not
accompanied by nausea, vomit nor other migraine-like
features, but the child reported osmophobia during some
headache attacks. Owing to his headache, the child had
stopped practicing sport.
At the time of the ﬁrst consultation in our centre, A.
was assuming paracetamol 500 mg/day as a prophylactic
Table 1 Diagnostic criteria for paroxysmal hemicrania (ICHD-II)
A. At least 20 attacks fulﬁlling criteria B–D
B. Attacks of severe unilateral supra-/orbital temporal pain lasting
2–30 min
C. Headache is accompanied by at leats 1 of the following:
1. Ipsilateral conjunctival injection and/or lachrymation
2. Ipsilateral nasal congestion and/or rhinorrhea
3. Ipsilateral eyelid oedema
4. Ipsilateral forehead and facial sweating
5. Ipsilateral miosis/ptosis
D. Attacks with a frequency of[5/day for more than half the time
E. Attacks completely prevented by therapeutic doses of
indomethacin (mg kg
-1 day
-1)
F. Not attributed to another disorder
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123treatment, without any positive effect. Moreover, his par-
ents referred that other NSAIDs were attempted, unsuc-
cessfully. Neurological examination was normal; brain
MRI and blood tests did not show any abnormality. A. had
a positive familiar history of headache, as his mother suf-
fered from migraine attacks. No triggers factors were
identiﬁed. A psychological screening was not possible, as
the child could not speak Italian. Paracetamol and ibu-
prophen treatment were attempted without any positive
effect, because pain resolved in 30–40 min also without
medication.
To reduce the frequency of pain attacks, a prophylactic
treatment with topiramate (50 mg/day) was started, but it
proved ineffective. The clinical characteristics of our
child’s headache and the failure of the traditional symp-
tomatic and prophylactic treatments led us to consider the
diagnosis of CPH. Therefore, indomethacin 50 mg/day was
started, soon affecting the frequency of the attacks, which
were no longer present after the second administration.
A., who is continuing the indomethacin therapy at the same
dose, has not suffered from any headache attack for the last
6 months. This has brought a signiﬁcant improvement to
his quality of life.
Discussion
The present study describes two cases of CPH in paediatric
age. Clinical symptoms and pain characteristics of our
children are similar to those found in typical adult CPH.
L. and A. presented with a long history of severe and uni-
lateral pain, which occurred in the fronto-orbital region
without side shift. As required by the current CPH deﬁnition
[3], attacks were accompanied by at least one autonomic
symptom, ipsilateral to pain. During the attacks, besides
conjunctival injection, eyelid oedema and rhinorrhea,
L. also presented vomiting and bilateral photophobia, which
are typical migraine features, common in CPH [5, 7, 10].
The main differential diagnosis of CPH is cluster
headache (CH). The relationship between CPH and CH is
uncertain. In the ICHD-II, there is a considerable over-
lapping between the diagnostic criteria for CPH and CH,
mostly concerning headache duration (from 15 to 30 min)
and attack frequency (from 5 to 8), thus complicating the
differential diagnosis. Moreover, also the behavioural
characteristics may not be useful in distinguishing CPH
from CH, since agitation, restlessness and aggressive
behaviour during pain attacks, typical of CH [20], have
been described also in some CPH cases [7, 12]. Pain site
and associated autonomic phenomena are similar in both
headaches, but the higher frequency of the attacks, their
shorter duration and the absolute response to indomethacin
may help in distinguishing CPH from CH [3].
Although CPH is commonly considered to prevail
amongst female patients, many CPH cases in paediatric age
are males [9–11, 13], as the children we described. In line
with the previous cases of CPH reported during develop-
mental age, our patients showed some atypical features, not
fully meeting the ICHD-II criteria. First, although the
ICHD-II criteria require an attack frequency higher than 5
attacks per day, in our patients, the attack frequency was
lower. This could be in favour of a diagnosis of CH, but an
attack frequency lower than the one required by the ICHD-
II criteria has been described in CPH of both childhood [11,
13, 18] and adulthood [4–6]. Moreover, according to
ICDH-II criteria, the attack frequency needed for diag-
nosing CPH should be higher than 5 per day, not con-
stantly, but for at least half the time of observation. Second,
attack duration was variable in both our children, but in A.
it was sometimes longer than 30 min, which represents the
maximal duration for a CPH attack, according to the
ICHD-II criteria. However, several reports showed CPH
patients with attack duration longer than 30 min in both
adults [5, 7] and children [8, 9]. Frequency and duration of
the attacks, nevertheless, are commonly different between
paediatric and adult population also in more common pri-
mary headaches, such as migraine and tension-type head-
ache. If attack duration and frequency can make the
diagnosis more difﬁcult, especially in paediatric age, the
absolute response to indomethacin represents the diagnos-
tic key for CPH in both adults and children (indotest) [3,
21]. Indeed, it is noteworthy that our children showed a
dramatic response to indomethacin. In particular, L. did not
respond to amitriptyline, as a prophylactic drug, nor to
common NSAIDs. Moreover, after an initial response to
indomethacin, the headache attacks increased their fre-
quency after the voluntary discontinuation of the drug.
They were markedly reduced when indomethacin was
resumed. To avoid a prolonged treatment with a high
indomethacin dose, topiramate was added, with a satis-
factory clinical response, as suggested by previous studies
on CPH [9, 22, 23]. Owing to cognitive adverse events,
topiramate was replaced with valproate, which was effec-
tive, as well. To our knowledge, there are no studies
showing the efﬁcacy of valproate in CPH. A. did not show
any improvement when treated with paracetamol and to-
piramate, whereas headache attacks disappeared after
indomethacin was started. In none of the patients, triptans
were tested, since both of them are under 12, and at their
age the use of triptans is not allowed in Italy.
Long-term therapy with indomethacin is generally well
tolerated [24], but adverse side effects may occur both in
adulthood and childhood [9, 22]. Nevertheless both our
children tolerated the therapy without any problem.
In conclusion, the characteristics of our children’s head-
ache, particularly the positive response to indomethacin, led
266 J Headache Pain (2011) 12:263–267
123us to consider the diagnosis of CPH. However, the fre-
quency and duration of our patient attacks did not fulﬁl the
ICHD-II criteria. CPH diagnosis can be difﬁcult in devel-
opmental age, due to the frequency and duration of attacks.
Although attacks should not be longer than 30 min [3], in
children’s CPH, the headache duration can exceed 40 min
[8, 9, 16]. Moreover, although the ICHD-II criteria for CPH
require an attack frequency higher than 5 per day, many
CPH children show a lower attack frequency (2–3 per day
or less) [8, 11, 13, 18]. These elements suggest that a
revision of the current CPH diagnostic criteria, possibly
with the inclusion of special notes for developmental age,
would be necessary.
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